Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study (Casper)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01904799|
Recruitment Status : Recruiting
First Posted : July 22, 2013
Last Update Posted : April 13, 2018
After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions.
The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not suitable for aphasic patients because they contain items with a strictly verbal response. Because of this, inexperienced doctors cannot evaluate higher functions (other than language) of aphasics in routine practice. For the same reason, aphasics are regularly excluded from post-cva therapeutic protocols, whether or not the trial bears on the evolution of cognitive functions.
Nonetheless, it is possible to evaluate, at least roughly, all of the cognitive functions without resorting to language.
The investigator have developed , from validated tests and classical clinical manoeuvers, the Cognitive Assessment for Stroke Patients (CASP) :
- for the rapid screening (less than 15 minutes) and quantification of post-cva cognitive disorders (6 functions: language, apraxia, short-term memory, temporal orientation, impaired spatial/visio-construction and executive functions);
- the CASP can be used in most patients, including those with severe disorders of expression and moderate problems with comprehension, The format of these tests has been adapted so that severe disorders of expression (essentially left-hemisphere CVA), and left spatial impairment (right-hemisphere CVA) do not affect the ability to take the test. Its validity in terms of appearance and content were verified in 2011.
|Condition or disease||Intervention/treatment||Phase|
|Stroke||Other: Cognitive Assessment test||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||290 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||December 2019|
|Cognitive Assessment||Other: Cognitive Assessment test|
- comprehensive assessment battery of higher functions [ Time Frame: baseline ]
- comprehensive assessment battery of higher functions [ Time Frame: Evaluation at 3 ±1 days ]
- comprehensive assessment battery of higher functions [ Time Frame: Evaluation at 6 ± 2 weeks ]
- test of visual memory [ Time Frame: baseline ]
- test of visual memory [ Time Frame: Evaluation at 3 ±1 days ]
- test of visual memory [ Time Frame: Evaluation at 6 ± 2 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904799
|CHU de Dijon||Recruiting|
|Dijon, France, 21079|
|Contact: Charles BENAIM firstname.lastname@example.org|
|Principal Investigator: Charles Benaim|